Added to YB: 2026-06-12
Pitch date: 2026-06-10
TVTX [neutral]
Travere Therapeutics, Inc.
+5%
current return
Author Info
No bio for this author
Company Info
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Market Cap
$4.3B
Pitch Price
$46.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
215.22
P/E
-92.27
EV/Sales
8.22
Sector
Biotechnology
Category
growth
GS Healthcare Conference – Recap part 1 (Day 2) - Travere Therapeutics, Inc.
TVTX (overview): Rare kidney disease platform anchored by FILSPARI (sparsentan), first FDA-approved FSGS therapy w/ strong uptake, faster launch vs IgA nephropathy, good payer acceptance. 5yr DUPLEX OLE shows durable proteinuria reduction. Pipeline: pegabatinase Ph3 (H2'27), BTK inhibitor. Self-funded, strong balance sheet. M&A score 75.
Read full article (1 min)